Tscan Therapeutics Inc (TCRX NASDAQ) stock market data APIs
$1.159
-0.04(-3.5%)
as of November 6, 2025
Try our APIs with
free plan!
Tscan Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Prev. Close
1.159
Open
1.1176
High
1.164
Low
1.0826
52 wk Range
1.02-5.92
Market Cap
65 828 K
Shares Outstanding
52 471 K
Revenue
6 961 K
EPS
0
Beta
0.999
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Tscan Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tscan Therapeutics Inc data using free add-ons & libraries
Get Tscan Therapeutics Inc Fundamental Data
Tscan Therapeutics Inc Fundamental data includes:
- Net Revenue: 6 961 K
- EBITDA: -141 123 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -0.3367
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tscan Therapeutics Inc News
New
Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to a loss of $0.68 per share a year ago. These figures are ...
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioriti...
Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $2.9 per share, beating the Zacks Consensus Estimate of $1.67 per share. This compares to a loss of $0.5 per share a year ago. These ...
2 Overlooked Stocks to Snap Up in 2025
While investors chase the usual market darlings, a few underappreciated businesses are quietly gaining traction by generating actual revenue growth, expanding margins, and setting themselves up for lo...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
